Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
Angew Chem Int Ed Engl
; 60(17): 9467-9473, 2021 04 19.
Article
in English
| MEDLINE | ID: covidwho-1037522
ABSTRACT
The search for vaccines that protect from severe morbidity and mortality because of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19) is a race against the clock and the virus. Here we describe an amphiphilic imidazoquinoline (IMDQ-PEG-CHOL) TLR7/8 adjuvant, consisting of an imidazoquinoline conjugated to the chain end of a cholesterol-poly(ethylene glycol) macromolecular amphiphile. It is water-soluble and exhibits massive translocation to lymph nodes upon local administration through binding to albumin, affording localized innate immune activation and reduction in systemic inflammation. The adjuvanticity of IMDQ-PEG-CHOL was validated in a licensed vaccine setting (quadrivalent influenza vaccine) and an experimental trimeric recombinant SARS-CoV-2 spike protein vaccine, showing robust IgG2a and IgG1 antibody titers in mice that could neutralize viral infection in vitro and in vivo in a mouse model.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Quinolines
/
Adjuvants, Immunologic
/
COVID-19 Vaccines
/
COVID-19
/
Imidazoles
/
Immunity, Innate
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Angew Chem Int Ed Engl
Year:
2021
Document Type:
Article
Affiliation country:
Anie.202015362
Similar
MEDLINE
...
LILACS
LIS